The Crisis of Care: Caily Confronts Caregiver Burnout with Launch of Comprehensive Digital Platform in Summer 2025
Denver, CO, June 02, 2025 (GLOBE NEWSWIRE) -- As caregiver burnout reaches…
Semilux Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 20-F
June 02, 2025 19:30 ET Â | Source: Semilux International Ltd. Taipei, Taiwan,…
FansHash Empowers Global Investors with Daily Passive Income via Cloud Mining
London, UK, June 02, 2025 (GLOBE NEWSWIRE) -- As Bitcoin approaches its…
MDB Capital Holdings Announces Transitions In Its Board of Directors
Addison, TX, June 02, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC,…
SunnyMining Gains Institutional Interest as Cloud Mining Sees Accelerated Adoption
Boston, Massachusetts, June 02, 2025 (GLOBE NEWSWIRE) -- SunnyMining's latest report shows…
Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
June 02, 2025 04:00 ET Â | Source: Aravax MELBOURNE, Australia and OXFORD,…
Press Release Biocartis NV: Biocartis Announces IVDR Class C CDx Certification of the Idylla EGFR Mutation Test
PRESS RELEASE 02/06/2025, 10:00 CEST Biocartis Announces IVDR Class C CDx Certification…
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition…
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
 Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…